MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Departure of Chief Medical Officer
March 04, 2020 17:00 ET | MacroGenics, Inc.
Rockville, MD, March 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
February 27, 2020 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and 2019 Financial Results
February 25, 2020 16:01 ET | MacroGenics, Inc.
Margetuximab: BLA for metastatic HER2-positive breast cancer accepted for review by the FDA; Phase 2/3 MAHOGANY study ongoing in front-line advanced HER2-positive gastric cancerFirst clinical data...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call
February 13, 2020 07:30 ET | MacroGenics, Inc.
Rockville, MD, Feb. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
February 10, 2020 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 10, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Present at the J.P. Morgan Healthcare Conference
January 13, 2020 07:30 ET | MacroGenics, Inc.
Rockville, MD, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Outlines Corporate Priorities for 2020
January 09, 2020 16:30 ET | MacroGenics, Inc.
Rockville, MD, Jan. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA
December 19, 2019 12:00 ET | MacroGenics, Inc.
ROCKVILLE, MD, Dec. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
December 11, 2019 10:00 ET | MacroGenics, Inc.
Rockville, MD, Dec. 11, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
December 09, 2019 15:05 ET | MacroGenics, Inc.
Rockville, MD, Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...